Cellumen has spun off its personalized medicine unit, which will be called Cernostics Pathology. The new entity will provide tissue-based diagnostic products and services as well as digital imaging pathology.
Cernostics Pathology will build upon Cellumen’s current collaborations. The first diagnostic/theranostic test being developed is for breast cancer as part of an alliance with the Mayo Clinic and Foundation.
"Cellumen’s successful application of cellular systems biology to drug discovery, drug development, and personalized medicine over the last three years has yielded strong interest across each of these application areas,” comments D. Lansing Taylor, Ph.D., CEO of Cellumen. “Cellumen will maintain its core business by focusing on the interface between early drug discovery and early toxicity testing.”
Cernostics Pathology will also create a complete digital imaging pathology platform and build advanced informatics tools to manage, mine, and classify patient tissue samples.